Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 26

1.

Rational Combinations of Targeted Agents in AML.

Bose P, Grant S.

J Clin Med. 2015 Apr 10;4(4):634-64. doi: 10.3390/jcm4040634. eCollection 2015 Apr. Review.

2.

Histone deacetylase inhibitor (HDACI) mechanisms of action: emerging insights.

Bose P, Dai Y, Grant S.

Pharmacol Ther. 2014 Sep;143(3):323-36. doi: 10.1016/j.pharmthera.2014.04.004. Epub 2014 Apr 24. Review.

3.

SAHA and S116836, a novel tyrosine kinase inhibitor, synergistically induce apoptosis in imatinib-resistant chronic myelogenous leukemia cells.

Bu Q, Cui L, Li J, Du X, Zou W, Ding K, Pan J.

Cancer Biol Ther. 2014 Jul;15(7):951-62. doi: 10.4161/cbt.28931. Epub 2014 Apr 23.

4.

Combination of bortezomib and mitotic inhibitors down-modulate Bcr-Abl and efficiently eliminates tyrosine-kinase inhibitor sensitive and resistant Bcr-Abl-positive leukemic cells.

Bucur O, Stancu AL, Goganau I, Petrescu SM, Pennarun B, Bertomeu T, Dewar R, Khosravi-Far R.

PLoS One. 2013 Oct 14;8(10):e77390. doi: 10.1371/journal.pone.0077390. eCollection 2013.

5.

A phase I study of vorinostat in combination with bortezomib in patients with advanced malignancies.

Schelman WR, Traynor AM, Holen KD, Kolesar JM, Attia S, Hoang T, Eickhoff J, Jiang Z, Alberti D, Marnocha R, Reid JM, Ames MM, McGovern RM, Espinoza-Delgado I, Wright JJ, Wilding G, Bailey HH.

Invest New Drugs. 2013 Dec;31(6):1539-46. doi: 10.1007/s10637-013-0029-6. Epub 2013 Oct 10.

6.

Combined effects of PI3K and SRC kinase inhibitors with imatinib on intracellular calcium levels, autophagy, and apoptosis in CML-PBL cells.

Ciarcia R, Damiano S, Montagnaro S, Pagnini U, Ruocco A, Caparrotti G, d'Angelo D, Boffo S, Morales F, Rizzolio F, Florio S, Giordano A.

Cell Cycle. 2013 Sep 1;12(17):2839-48. doi: 10.4161/cc.25920. Epub 2013 Aug 8.

7.

Aclacinomycin A sensitizes K562 chronic myeloid leukemia cells to imatinib through p38MAPK-mediated erythroid differentiation.

Lee YL, Chen CW, Liu FH, Huang YW, Huang HM.

PLoS One. 2013 Apr 17;8(4):e61939. doi: 10.1371/journal.pone.0061939. Print 2013.

8.

Targeting survival pathways in chronic myeloid leukaemia stem cells.

Sinclair A, Latif AL, Holyoake TL.

Br J Pharmacol. 2013 Aug;169(8):1693-707. doi: 10.1111/bph.12183. Review.

9.

PLK1 inhibitors synergistically potentiate HDAC inhibitor lethality in imatinib mesylate-sensitive or -resistant BCR/ABL+ leukemia cells in vitro and in vivo.

Dasmahapatra G, Patel H, Nguyen T, Attkisson E, Grant S.

Clin Cancer Res. 2013 Jan 15;19(2):404-14. doi: 10.1158/1078-0432.CCR-12-2799. Epub 2012 Nov 30.

10.

SIRT1 deacetylase promotes acquisition of genetic mutations for drug resistance in CML cells.

Wang Z, Yuan H, Roth M, Stark JM, Bhatia R, Chen WY.

Oncogene. 2013 Jan 31;32(5):589-98. doi: 10.1038/onc.2012.83. Epub 2012 Mar 12.

11.

Endogenous modulators and pharmacological inhibitors of histone deacetylases in cancer therapy.

Spiegel S, Milstien S, Grant S.

Oncogene. 2012 Feb 2;31(5):537-51. doi: 10.1038/onc.2011.267. Epub 2011 Jul 4. Review.

12.

The MEK inhibitor PD184352 enhances BMS-214662-induced apoptosis in CD34+ CML stem/progenitor cells.

Pellicano F, Simara P, Sinclair A, Helgason GV, Copland M, Grant S, Holyoake TL.

Leukemia. 2011 Jul;25(7):1159-67. doi: 10.1038/leu.2011.67. Epub 2011 Apr 12.

13.

HDAC inhibitors potentiate the activity of the BCR/ABL kinase inhibitor KW-2449 in imatinib-sensitive or -resistant BCR/ABL+ leukemia cells in vitro and in vivo.

Nguyen T, Dai Y, Attkisson E, Kramer L, Jordan N, Nguyen N, Kolluri N, Muschen M, Grant S.

Clin Cancer Res. 2011 May 15;17(10):3219-32. doi: 10.1158/1078-0432.CCR-11-0234. Epub 2011 Apr 7.

14.

Phase I study of vorinostat in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study.

Ramalingam SS, Kummar S, Sarantopoulos J, Shibata S, LoRusso P, Yerk M, Holleran J, Lin Y, Beumer JH, Harvey RD, Ivy SP, Belani CP, Egorin MJ.

J Clin Oncol. 2010 Oct 10;28(29):4507-12. doi: 10.1200/JCO.2010.30.2307. Epub 2010 Sep 13.

15.

Novel pyrrolo-1,5-benzoxazepine compounds display significant activity against resistant chronic myeloid leukaemia cells in vitro, in ex vivo patient samples and in vivo.

Bright SA, McElligott AM, O'Connell JW, O'Connor L, Carroll P, Campiani G, Deininger MW, Conneally E, Lawler M, Williams DC, Zisterer DM.

Br J Cancer. 2010 May 11;102(10):1474-82. doi: 10.1038/sj.bjc.6605670. Epub 2010 Apr 20.

16.

The bone marrow microenvironment as a sanctuary for minimal residual disease in CML.

Nair RR, Tolentino J, Hazlehurst LA.

Biochem Pharmacol. 2010 Sep 1;80(5):602-12. doi: 10.1016/j.bcp.2010.04.003. Epub 2010 Apr 9. Review.

17.

A phase 2 study of vorinostat in acute myeloid leukemia.

Schaefer EW, Loaiza-Bonilla A, Juckett M, DiPersio JF, Roy V, Slack J, Wu W, Laumann K, Espinoza-Delgado I, Gore SD; Mayo P2C Phase II Consortium.

Haematologica. 2009 Oct;94(10):1375-82. doi: 10.3324/haematol.2009.009217.

18.

Inhibitors of deacetylases suppress oncogenic KIT signaling, acetylate HSP90, and induce apoptosis in gastrointestinal stromal tumors.

M├╝hlenberg T, Zhang Y, Wagner AJ, Grabellus F, Bradner J, Taeger G, Lang H, Taguchi T, Schuler M, Fletcher JA, Bauer S.

Cancer Res. 2009 Sep 1;69(17):6941-50. doi: 10.1158/0008-5472.CAN-08-4004. Epub 2009 Aug 25.

19.

Vorinostat in solid and hematologic malignancies.

Siegel D, Hussein M, Belani C, Robert F, Galanis E, Richon VM, Garcia-Vargas J, Sanz-Rodriguez C, Rizvi S.

J Hematol Oncol. 2009 Jul 27;2:31. doi: 10.1186/1756-8722-2-31. Review.

20.

Abrogation of mitogen-activated protein kinase and Akt signaling by vandetanib synergistically potentiates histone deacetylase inhibitor-induced apoptosis in human glioma cells.

Jane EP, Premkumar DR, Addo-Yobo SO, Pollack IF.

J Pharmacol Exp Ther. 2009 Oct;331(1):327-37. doi: 10.1124/jpet.109.155705. Epub 2009 Jul 21.

Items per page

Supplemental Content

Write to the Help Desk